Prestige Consumer Healthcare (PBH) Cost of Revenue (2010 - 2025)
Prestige Consumer Healthcare (PBH) posted quarterly Cost of Revenue of $126.1 million for Q4 2025, down 1.01% year-over-year from $127.4 million in Q4 2024, and up 5.02% quarter-over-quarter from $120.0 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Cost of Revenue (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Cost of Revenue history runs 16 years deep, the most recent figure standing at $126.1 million for Q4 2025.
- In Q4 2025, Cost of Revenue fell 1.01% year-over-year to $126.1 million; the TTM figure through Dec 2025 stood at $479.6 million (down 5.21% YoY), while the FY2025 annual figure was $494.4 million, down 1.3% from the prior year.
- Cost of Revenue for Q4 2025 stood at $126.1 million, up from $120.0 million in the prior quarter.
- The five-year high for Cost of Revenue was $132.1 million in Q1 2023, with the low at $105.3 million in Q1 2021.
- The 5-year median for Cost of Revenue is $123.6 million (2023), against an average of $121.4 million.
- The sharpest annual moves came in 2021 and 2025: Cost of Revenue rose 20.64% in 2021, then dropped 9.84% in 2025.
- Prestige Consumer Healthcare's Cost of Revenue stood at $119.4 million in 2021, then advanced by 4.78% to $125.1 million in 2022, then slipped by 1.86% to $122.8 million in 2023, then advanced by 3.72% to $127.4 million in 2024, then declined by 1.01% to $126.1 million in 2025.
- Business Quant data shows PBH's Cost of Revenue at $126.1 million in Q4 2025, $120.0 million in Q3 2025, and $109.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Prestige Consumer Healthcare | 2.42 Bn | 2.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 126.08 Mn |
| Dec 31, 2025 | 126.08 Mn |
| Sep 30, 2025 | 120.04 Mn |
| Sep 30, 2025 | 120.04 Mn |
| Jun 30, 2025 | 109.20 Mn |
| Jun 30, 2025 | 109.20 Mn |
| Mar 31, 2025 | 124.32 Mn |
| Mar 31, 2025 | 124.32 Mn |
| Dec 31, 2024 | 127.36 Mn |
| Dec 31, 2024 | 127.36 Mn |
| Sep 30, 2024 | 126.40 Mn |
| Sep 30, 2024 | 126.40 Mn |
| Jun 30, 2024 | 121.12 Mn |
| Jun 30, 2024 | 121.12 Mn |
| Mar 31, 2024 | 131.14 Mn |
| Mar 31, 2024 | 131.14 Mn |
| Dec 31, 2023 | 122.79 Mn |
| Dec 31, 2023 | 122.79 Mn |
| Sep 30, 2023 | 126.30 Mn |
| Sep 30, 2023 | 126.30 Mn |